There are a number of symptoms for Covid-19 – Fever or chills, cough, shortness of breath, fatigue, muscle or body aches, headache, recent loss of taste of smell, sore throat, congestion or runny nose, nausea, diarrhoea etc.
Three of the top five symptoms for Covid-19 deal with respiratory issues. Using Swaasa RTW, one can detect respiratory issues and so provide a good indicator of possible COVID-19 infection.
Unlike a PCR test, It is not a definitive test for COVID19 but can be an effective way to enhance risk assessment.
Swaasa RTW uses a combination of (a) Symptoms (b) Body temperature (c ) Oxygen saturation and (d) Cough analysis to categorize employees who are safe to work and who are advised caution. Our integrated status of an individual has been developed with inputs from those in the medical profession.
Swaasa’s capabilities are delivered through web and mobile channels. This becomes an easy way for individuals/employees to perform risk assessments remotely at the comfort of their homes. Before leaving for work, this risk assessment is a valuable method in managing risks to an organization and its employees.
Swaasa has completed WHO defined clinical trial (https://apps.who.int/trialsearch/Trial2.aspx?TrialID=CTRI/2018/08/015237) and is in the process of FDA approval to enable it being treated as a medical device. Once approved, it will be considered equivalent of using a spirometer, the gold standard in lung function testing.
In the context of Covid-19, we adopt the same proven technology to enhance risk assessments alone (we do not provide medical diagnostics until we have the right approvals in place).
Swaasa enables monitoring of temperature , symptoms and respiratory conditions using oxygen saturation and cough analysis at individual employee level. All this being done in a contactless, easy to use and automated manner.
Moreover it also provides organization level dashboards and trends to not only look at a longitudinal view of individual data but also review group level information to make the right management decision.
Swaasa RTW offers a loosely coupled integration with the organisations’ systems. A more tightly integrated solution can be offered by engaging our Software Services team.
Swaasa AI uses anonymised data. All PHI resides in the employer’s systems or in a secure cloud compliant per industry standards, within the organization’s firewall..
Employers have the option to manually set clearances for any particular employee, thereby overriding the assessment of the system. This can be done after the due verification process defined by each organization.
The cough sample given by an employee may be voluntary or involuntary. In other words the employee does not have to be suffering from cough for the product to be able to assess lung health.
Swaasa offers the additional parameter of lung-health assessment in assessing the risk level of an employee in addition to conventional questionnaire based assessment. Since Covid-19 is essentially an infection of the lungs, it is an important addition in providing a more comprehensive risk assessment.
Swaasa performs well w.r.t “Test-Retest” variability. This has been tested in various scenarios.
We are authorized for use as a Medical device (software as a medical device) in India. We are pursuing regulatory approvals in the USA, Canada, and Australia for our “core” medical application as Software as a Medical Device.
ReWell MD was the original name of the respiratory health assessment platform developmed by Salcit Technologies Private Limited, which has been renamed as SwaasaTM.